<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04451785</url>
  </required_header>
  <id_info>
    <org_study_id>69HCL19_0949</org_study_id>
    <secondary_id>2019-A03203-54</secondary_id>
    <nct_id>NCT04451785</nct_id>
  </id_info>
  <brief_title>Hereditary Spherocytosis and Vascular Function</brief_title>
  <acronym>VASCUSPHERO</acronym>
  <official_title>Relationships Between Hemolysis, Erythrosis, Circulating Microparticles and Vascular Function in Patients With Hereditary Spherocytosis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Hospices Civils de Lyon</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Hospices Civils de Lyon</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Background : Patients with hereditary spherocytosis (HS) are characterized by increased red&#xD;
      blood cell (RBC) fragility and a loss of RBC deformability. While the clinical variability of&#xD;
      the disease may be heterogenous from one patient to another, some studies reported the&#xD;
      occurrence of vascular complications, notably in patients who have been splenectomized.&#xD;
&#xD;
      Purpose : The aim of the study is to test the associations between the degree of vascular&#xD;
      dysfunction and the extent of hemolysis, the amount of circulating microparticles, the level&#xD;
      of erythrosis and the degree of RBC biophysical alterations.&#xD;
&#xD;
      Abstract : Recent studies reported the occurrence of vascular complications in patients with&#xD;
      HS, notably in patients who have previously been splenectomized. However, the exact reasons&#xD;
      of these complications are unknown and no study investigated the vascular function in HS&#xD;
      patients.&#xD;
&#xD;
      Main objective Highlight the presence of altered vascular function in HS patients and test&#xD;
      the relationships with the level of hemolysis and circulating microparticles.&#xD;
&#xD;
      Secondary objectives To evaluate the associations between clinical severity and 1) the level&#xD;
      of vascular dysfunction and 2) several biomarkers (hemolysis, hematological parameters,&#xD;
      circulating microparticles, erythrosis, RBC biophysical properties).&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">August 1, 2020</start_date>
  <completion_date type="Anticipated">August 1, 2022</completion_date>
  <primary_completion_date type="Anticipated">August 1, 2022</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>measurement of pulse wave velocity (PWV)</measure>
    <time_frame>Day 1</time_frame>
    <description>Vascular function (arterial stiffness) will be investigated by the measurement of pulse wave velocity (PWV). Vascular dysfunction will be defined by a PWV value higher than 6 meter/second (m/s) and 10 m/s in children and adults with HS, respectively.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Hemogram</measure>
    <time_frame>Day 1</time_frame>
    <description>The hemogram is a complete blood count of the different cell types. All these measures are performed simultaneously on a standard hematology analyzer.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Markers of hemolysis</measure>
    <time_frame>Day 1</time_frame>
    <description>These markers are measured simultaneously on a standard biochemistry analyzer</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Circulating microparticles</measure>
    <time_frame>Day 1</time_frame>
    <description>Circulating microparticles of various cell origin will be measured by flow cytometry</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Markers of erythrosis</measure>
    <time_frame>Day 1</time_frame>
    <description>Markers of erythrosis (i.e., suicidal death of red blood cells) will be measured by flow cytometry</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Blood viscosity</measure>
    <time_frame>Day 1</time_frame>
    <description>Blood viscosity (expressed in Pa.s) will be measured on a cone-plate viscosimeter, ektacytometry and light transmission, respectively.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Red blood cell deformability</measure>
    <time_frame>Day 1</time_frame>
    <description>Red blood cell deformability will be measured simultaneously on a Lorrca ektacytometry (Laser-assisted Rotational Red Cell Analyser).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Red blood cell aggregation</measure>
    <time_frame>Day 1</time_frame>
    <description>Red blood cell aggregation will be measured simultaneously on a Lorrca ektacytometry (Laser-assisted Rotational Red Cell Analyser).</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">80</enrollment>
  <condition>Hereditary Spherocytosis</condition>
  <arm_group>
    <arm_group_label>Healthy individuals</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>20 healthy subjets aged 6 years minimum will be included in this study. This is the control group.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Patients with hereditary spherocytosis</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>60 patients with hereditary spherocytosis will be included in this study.</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>blood sample</intervention_name>
    <description>6 tubes of 4 milliliters (ml) maximum (total: 24 ml) will be sampled for the measurements of the different biological markers. In case of the genetic mutation is already known, only 5 tubes will be collected (total: 20 ml).</description>
    <arm_group_label>Healthy individuals</arm_group_label>
    <arm_group_label>Patients with hereditary spherocytosis</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Diagnostic Test</intervention_type>
    <intervention_name>Pulse wave velocity</intervention_name>
    <description>Non-invasive measurement of pulse wave velocity between the carotid and femoral arteries with piezo-electric sensors.</description>
    <arm_group_label>Healthy individuals</arm_group_label>
    <arm_group_label>Patients with hereditary spherocytosis</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
        Healthy controls:&#xD;
&#xD;
          -  age ≥ 6 years old&#xD;
&#xD;
          -  written, informed and signed consent by the healthy volunteer, or by both parents or&#xD;
             legal guardian if the healthy volunteer is a minor&#xD;
&#xD;
          -  Healthy volunteer affiliated to a social security scheme or assimilated&#xD;
&#xD;
          -  Healthy volunteer not subject to any legal protection measure&#xD;
&#xD;
        Patients with hereditary spherocytosis:&#xD;
&#xD;
          -  age ≥ 6 years old&#xD;
&#xD;
          -  Patient with hereditary or non-splenectomized spherocytosis&#xD;
&#xD;
          -  Written, informed and signed consent by the patient, or by at least one of the two&#xD;
             parents or legal guardian if the patient is a minor&#xD;
&#xD;
          -  Patient affiliated to a social security scheme or assimilated&#xD;
&#xD;
          -  Patient not subject to any legal protection measure&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
        Healthy controls:&#xD;
&#xD;
          -  Pregnant or lactating woman&#xD;
&#xD;
          -  Subjects with hereditary spherocytosis or other characterized condition by chronic&#xD;
             hemolysis&#xD;
&#xD;
          -  Subjects with known pathology affecting the vascular system&#xD;
&#xD;
          -  Blood donation (less than a month old)&#xD;
&#xD;
          -  Not affiliated to a social security scheme&#xD;
&#xD;
          -  Patient participating in another interventional research protocol that may interfere&#xD;
             with this protocol (according to the investigator's judgment).&#xD;
&#xD;
        Patients with hereditary spherocytosis:&#xD;
&#xD;
          -  Patient who received a blood transfusion in the 3 months preceding&#xD;
&#xD;
          -  Pregnant or lactating woman&#xD;
&#xD;
          -  Any disease or condition other than hereditary spherocytosis, chronic or not, likely&#xD;
             to induce chronic or acute intravascular hemolysis&#xD;
&#xD;
          -  Patient participating in another interventional research protocol that may interfere&#xD;
             with this protocol (according to the investigator's judgment).&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>6 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Alexandra GAUTHIER-VASSEROT, MD,PHD</last_name>
    <phone>04 69 16 65 72</phone>
    <phone_ext>+33</phone_ext>
    <email>alexandra.gauthier@ihope.fr</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Philippe CONNES</last_name>
    <phone>04 72 43 16 25</phone>
    <phone_ext>+33</phone_ext>
    <email>philippe.connes@univ-lyon1.fr</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Institut d'Hématologie et Oncologie PEdiatrique (iHOPe)</name>
      <address>
        <city>Lyon</city>
        <zip>69373</zip>
        <country>France</country>
      </address>
    </facility>
    <contact>
      <last_name>Alexandra GAUTHIER-VASSEROT, MD,PhD</last_name>
      <phone>04 69 16 65 72</phone>
      <phone_ext>+33</phone_ext>
      <email>alexandra.gauthier@ihope.fr</email>
    </contact>
    <investigator>
      <last_name>Alexandra GAUTHIER-VASSEROT, MD,PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Yves BERTRAND, PU,PH</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Kamila KEBAILI, MD,PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Céline RENARD, MD,PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Nathalie GARNIER, MD,PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hôpital Edouard Herriot</name>
      <address>
        <city>Lyon</city>
        <zip>69437</zip>
        <country>France</country>
      </address>
    </facility>
    <contact>
      <last_name>Giovanna CANNAS, MD,PhD</last_name>
      <phone>04 72 11 74 12</phone>
      <phone_ext>+33</phone_ext>
      <email>giovanna.cannas@chu-lyon.fr</email>
    </contact>
    <investigator>
      <last_name>Giovanna CANNAS, MD,PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Arnaud HOT, PU,PH</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Romain FORT, MD,PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Solène POUTREL, MD,PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>June 2020</verification_date>
  <study_first_submitted>June 18, 2020</study_first_submitted>
  <study_first_submitted_qc>June 25, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">June 30, 2020</study_first_posted>
  <last_update_submitted>June 25, 2020</last_update_submitted>
  <last_update_submitted_qc>June 25, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">June 30, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Hereditary spherocytosis</keyword>
  <keyword>hemolysis</keyword>
  <keyword>microparticles</keyword>
  <keyword>vascular function</keyword>
  <keyword>red blood cell</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Spherocytosis, Hereditary</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

